(HealthDay)—Disease-modifying antirheumatic drugs (DMARDs) may be underutilized for treatment of low back pain (LBP), according to a review published online June 1 in Pain Practice.
3
0
The German Institute for Quality and Efficiency in Health Care (IQWiG) examined 9 biotechnologically produced drugs for the treatment of adults with rheumatoid arthritis in whom prior pharmacological treatment had failed. ...
0
0
(HealthDay)—The addition of tofacitinib to rheumatoid arthritis (RA) treatment regimens improves patient response to non-biologic disease-modifying antirheumatic drugs (DMARDs), according to a study published in the Aug. ...
0
0
(HealthDay)—Electronic monitoring shows that ethnically diverse and economically disadvantaged patients with rheumatoid arthritis (RA) have low adherence to oral disease-modifying antirheumatic drugs (DMARDs) and poorer ...
0
0
Data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate that indicators of depression are stronger predictors of work disability in early arthritis than disease activity ...
0
0
Patients with rheumatoid arthritis (RA) who initiated use of anti-tumor necrosis factor therapies were not at a higher risk of developing herpes zoster (shingles), compared with patients who initiated nonbiologic treatment ...
0
0
Although patients with rheumatoid arthritis (RA) have a disproportionately higher incidence of herpes zoster (shingles), an analysis that included nearly 60,000 patients with RA and other inflammatory diseases found that ...
0
0
Although there are concerns regarding the potential development of malignancies in patients with rheumatoid arthritis who are receiving treatment with biologic response modifiers (BRMs), pooled results from more than 60 randomized ...
0
0
The American College of Rheumatology (ACR) has released the 2012 recommendations for the use of disease-modifying antirheumatic drugs (DMARDs) and biologic agents in the treatment of rheumatoid arthritis (RA). The guidelines ...
0
0
Among patients with juvenile idiopathic arthritis (JIA) who initiated treatment with the drug etanercept, one-third achieved an excellent response, and this response was associated with low measures of disability at study ...
0
0
Subscribe to rss feed
